Skip to main content
SpringerLink
Log in

Syndrome X and the Benefits of Weight Loss

  • Chapter
The Management of Eating Disorders and Obesity

Part of the book series: Nutrition ◊ and ◊ Health ((NH))

  • 204 Accesses

Abstract

Obesity is the most common metabolic disorder in the Western world. Defined by a body mass index (BMI) equal to or greater than 30, it affects an estimated 33% of Americans, including more than 58 million adults in the United States (1). According to the National Institute of Health (NIH) guideline published in 1998, approximately 97 million or 55% of adults in the United States are overweight or obese (2). Though a major contributor to the cost of illness in the United States, the prevalence of obesity is increasing despite evidence indicating that weight loss, even if moderate, can improve health status and lessen the incidence of obesity-related disease (3–6). Studies show that a 10% decline in body weight cuts death and morbidity rates per million by 280 and 400, respectively (6,7).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 74.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Kuczmarski RJ, Flegal KM, Campbell SM, Johnson CL. Increasing prevalence of overweight among US adults: The National Health and Nutrition Examination Surveys, 1960–1991. JAMA 1994; 272: 205–211.

    Article  CAS  Google Scholar 

  2. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults—The Evidence Report. Obes Res 1998; 6 (2): 51S - 2105.

    Article  Google Scholar 

  3. Thomas PR. Weighing the options. In: Thomas PR. ed. Weighing the Options, Criteria for Evaluating Weight Management Programs. National Academy Press, Washington DC, 1995, pp. 91–93.

    Chapter  Google Scholar 

  4. Kanders BS, Blackburn GL. Health consequences of therapeutic weight loss: reducing primary risk factors. In: Wadden TA, Van Itallie TB, eds. The treatment of the seriously obese patient. Guilford, New York, NY, 1992, pp. 213–230.

    Google Scholar 

  5. Goldstein DJ. Beneficial health effects of a modest weight loss. Int J Obes 1992; 16: 397–415.

    CAS  Google Scholar 

  6. Manson JE, Willett WC, Stampfer MR, Colditz GA, Hunter DJ, Harkinson SE, et al. Body weight and mortality among women. N Engl J Med 1995; 333: 677–685.

    Article  CAS  Google Scholar 

  7. Manson JE, Faich GA. Pharmacotherapy for obesity. Do the benefits outweigh the risks? N Engl J Med 1996; 335: 659–660.

    Article  CAS  Google Scholar 

  8. McGinnis JM, Foege WH. Actual causes of death in the United States. JAMA 1993; 270: 2307–2312.

    Article  Google Scholar 

  9. Wolf AM, Colditz GA. The cost of obesity: the US perspective. PharmacoEconomics 1994; 5: 34–37.

    Article  CAS  Google Scholar 

  10. Wolf AM, Colditz GA. Current estimates of the economic cost of obesity in the United States. Obes Res 1998; 6: 97–106.

    Article  CAS  Google Scholar 

  11. National Center for Health Statistics (1989). Public use data documentation, part National Health Interview Survey, 1988 (machine readable data file and documentation). National Center for Health Statistics, Hyattsville, MD.

    Google Scholar 

  12. Colditz GA. Economic costs of obesity. Am J Clin Nutr 1992; 55: 5035–5075.

    Google Scholar 

  13. DeForonzo RA, Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14: 173–194.

    Article  Google Scholar 

  14. Lebovitz H, Banerji M, Chaiken R. The relationship between type II diabetes and syndrome X. Curr Opin Endocrinol and Diabetes 1995; 4: 307–312.

    Article  Google Scholar 

  15. Young TK, Gelskey D. Is non-central obesity metabolically benign? Implications for prevention from a population survey. JAMA 1995; 274: 1939–1941.

    Article  CAS  Google Scholar 

  16. Bonner G. Hyperinsulinemia, insulin resistance and hypertension. J Cardiovasc Pharmacol 1994; 24: S39 - S49.

    Google Scholar 

  17. Reaven G. Relationship between insulin resistance and hypertension. Diabetes Care 1994; 14: 33–39.

    Google Scholar 

  18. Landsberg L. Hyperinsulinemia: possible role in obesity-induced hypertension. Hypertension 1992; 19 (Suppl): 161S - 166S.

    Article  Google Scholar 

  19. Reaven G, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities: the role of insulin resistance and the sympatho-adrenal system. N Engl J Med 1996; 372: 374–380.

    Google Scholar 

  20. DeForonzo RA, Cooke C, Andres R, Faloona GR, Davis PJ. The effect of insulin in renal handling of sodium, potassium, calcium, and phosphate on men. J Clin Invest 1975; 55: 845–855.

    Article  Google Scholar 

  21. Baum M. Insulin stimulates volume absorption in rabbit proximal convoluted tubule. J Clin Invest 1975; 79: 1104–1109.

    Article  Google Scholar 

  22. Drazin B, Kao M, Sussman KE. Insulin and glyburide increase cytosolic free Ca concentration in osolated rat adipocyte. Diabetes 1987; 36: 174–178.

    Article  Google Scholar 

  23. Troisi R, Weiss D, Parker D, Sparrow D, Young J, Landsberg L. Relation of obesity and diet to sympathetic nervous system activity. Hypertension 1991; 17: 669–677.

    Article  CAS  Google Scholar 

  24. Maxwell M, Kushiro T, Dornfield L, Tuck M, Walks A. BP changes in obese hypertensive subjects during rapid weight loss. Arch Intern Med 1984; 144: 1581–1584.

    Article  CAS  Google Scholar 

  25. Rowe JW, Young JB, Mimaker KL, Stevens AL, Pallotta J, Landsberg L. Effects of insulin and glucose infusion on sympathetic nervous system activity in normal man. Diabetes 1981; 30: 219–225.

    CAS  Google Scholar 

  26. Hall J, Brands M, Hildebrandt D, Mizelle L. Obesity-associated hypertension, hyperinsulinemia and renal mechanisms. Hypertension 1992; 19: 145–155.

    Article  Google Scholar 

  27. Reisen E, Abel R, Modan M, Silverburg D, Eliahou H, Modan B. Effect of weight loss without salt restriction on the reduction of blood pressure in overweight hypertensive patients. N Engl J Med 1978; 298: 1–5.

    Article  Google Scholar 

  28. Nestel PJ, Whyte HM, Goodman DS. Distribution and turnover of cholesterol in humans. J Clin Invest 1969; 48: 982–991.

    Article  CAS  Google Scholar 

  29. Vaswani AN. Effect of weight reduction on circulating lipids: an integration of possible mechanisms. J Am Coll Nutr 1983; 2: 123–132.

    CAS  Google Scholar 

  30. Garg A. Insulin resistance in the pathogenesis of dyslipidemia. Diabetes Care 1996; 4: 387–388.

    Google Scholar 

  31. Howard B. Pathogenesis of diabetic dyslipidemia. Diabetes Rev 1995; 423–432.

    Google Scholar 

  32. Manson JE, Colditz GA, Stampfer MJ, Willett W, Rosner B, Monson R, et al. A prospective study of obesity and risk of coronary heart disease in women. N Engl J Med 1990; 322: 882–889.

    Article  CAS  Google Scholar 

  33. Despres JP, Lamarche B, Mauriege P, Cantin B, Dagenias G, Moorjani S, Lupien P. Hyperinsulinemia as an independent risk factor for ischemia heart disease. N Engl J Med 1996; 334: 952–957.

    Article  CAS  Google Scholar 

  34. Ferrannini E, Muscelli E, Stern MP, Haffner S. Differential impact of insulin and obesity on cardiovascular risk factors in non-diabetic subjects. Int J Obesity 1996; 20: 7–14.

    CAS  Google Scholar 

  35. Pfeile B, Ditschuneit H. Two separate receptors for insulin and insulin-like growth factor on arterial smooth muscle cells. Diabetologia 1981; 20: 155–158.

    Article  Google Scholar 

  36. Cruz AB, Amatuzi DS, Grande F, Hay LJ. Effect on inter-arterial insulin on tissue cholesterol and fatty acids in alloxan-diabetic dogs. Circ Res 1961; 9: 39–43.

    Article  CAS  Google Scholar 

  37. Shinozaki K, Suzuki M, Ikebuchi M, Hara Y, Harano Y. Demonstration of insulin resistance in coronary artery disease documented with angiography. Diabetes Care 1996; 19: 1–7.

    Article  CAS  Google Scholar 

  38. Kannel WB, Wolf PA, Castelli WP, D’ Agostino RB. Fibrinogen and risk of cardiovascular disease. JAMA 1987; 258: 1183–1186.

    Article  CAS  Google Scholar 

  39. Yarnell JWG, Baker IA, Sweetman PM, Bainton D, O’Brien JR, Whitehead PJ, Elwood PC. Fibrinogen, viscosity and white blood count are major risk factors for ischemic heart disease. Circulation 1991; 83: 836–844.

    Article  CAS  Google Scholar 

  40. Wilhelmsen L, Svardsudd K, Korsan-Bengsten K, Larsson B, Weilin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984; 311: 501–505.

    Article  CAS  Google Scholar 

  41. Bodonna R, Groop L, Kramer N, DeForonzo RA. Obesity and insulin resistance in man: a dose response study. Metabolism 1990; 39: 452–59.

    Article  Google Scholar 

  42. Golay A, Felber JP, Jequier, Deforonozo RA, Ferrannini E Metabolic basis of obesity and non-insulin dependent diabetes mellitus. Diabetes Metabol Rev 1988; 4: 727–747.

    CAS  Google Scholar 

  43. Reaven G. Banting Lecture: Role of insulin resistance in human disease. Diabetes 1989; 37: 1595–1607.

    Article  Google Scholar 

  44. Colditz GA, Willett W, Rotnitzky A, Manson JE. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med 1995; 122: 481–486.

    CAS  Google Scholar 

  45. Kelly D. Effects of weight loss on glucose homeostasis. Diabetes Rev 1995; 3: 366377.

    Google Scholar 

  46. Henry RR, Wallace P, Olefsky JM. Effects of weight loss on the mechanisms of hyperglycemia in obese non-insulin-dependent diabetes. Diabetes 1986; 35: 990–998.

    Article  CAS  Google Scholar 

  47. Wing RR, Koeske R, Epstein LH, Nowalk MP, Gooding W, Becker D. Long-term effects of modest weight loss in type II diabetic patients. Arch Intern Med 1987; 147: 1749–1753.

    Article  CAS  Google Scholar 

  48. Henry RR, Scheaffer L, Olefskyt JM. Glycemic effects of intensive caloric restriction and isocaloric refeeding in non-insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1985; 61: 917–925.

    Article  CAS  Google Scholar 

  49. Wall JR, Pyke DA, Oakley WG. Effect of carbohydrate restriction in obese diabetics: relationship of control to weight loss. Br Med J 1973; 10: 577–578.

    Article  Google Scholar 

  50. Kannel WB, Brand N, Skinner JJ, Jr, Dawber TR, McNamara PM. Relation of adiposity to blood pressure. Findings of the Framingham Study. Ann Intern Med 1978; 67: 48–59.

    Google Scholar 

  51. Stamler R, Stamler J, Reidlinger WF, Algera G, Roberts RH. Weight and blood pressure: findings in hypertension screening of 1 million Americans. JAMA 1978; 240: 1607–1610.

    Article  CAS  Google Scholar 

  52. Kanders B, Peterson F, Lavin P, Norton D, Istfan N, Blackburn GL. Long-term effects associated with significant weight loss: a study of the dose response effect. In: Blackburn GL, Kanders BS, eds. Obesity Pathophysiology, Psychology and Treatment. Chapman and Hall, New York, NY, pp. 167–184.

    Google Scholar 

  53. Wasserthei-Smoller, Obermsan A, Blaufox MD, Davis B, Langford H. The trial of antihypertensive interventions and management (TIAM) study. Final results with regard to blood pressure, cardiovascular risk and quality of life. Am J Hypertens 1992; 5: 37–44.

    Google Scholar 

  54. Katzel LI, Bleecker EU, Colman EG, Rogus EM, Sorkin JD, Goldberg AP. Effects of weight loss v. aerobic exercise training on risk factors for coronary disease in healthy obese, middle-aged and older men. JAMA 1995; 274: 1915–1921.

    Article  CAS  Google Scholar 

  55. Rocchini A, Katch V, Schork A, Kelch R. Insulin and blood pressure during weight loss in obese adolescents. Hypertension 1987; 10: 267–273.

    Article  CAS  Google Scholar 

  56. Maxwell M, Heber D, Waks A, Tuck M. Role of insulin and norepinephrine in the hypertension of obesity. Am J Hypertens 1994; 7: 402–408.

    CAS  Google Scholar 

  57. Datillo AM, Kris-Etherton PM. Effects of weight reduction on blood lipids and lipoproteins: a meta analysis. Am J Clin Nutrition 1992; 56: 320–328.

    Google Scholar 

  58. Ditschuneit H, Flechtner-Mors M, Adler G. Fibrinogen in obesity before and after weight reduction. Obes Res 1995; 3: 43–48.

    Article  CAS  Google Scholar 

  59. Fanari P, Somazzi R, Narsrawi F, Ticozelli P, Grugni G, Agosti R, Longhini E. Haemorheological changes in obese adolescents after short-term diet. Int J Obes Relat metab Disord 1993; 17: 487–494.

    CAS  Google Scholar 

  60. Anderson J, Felston DT. Factors associated with osteo-arthritis of the knee in the first National Health and Nutrition Examination Survey. Am J Epidemiol 1988; 128: 179–189.

    CAS  Google Scholar 

  61. Heliovaara M, Makela M, Impivaara O, Knect P, Aromaa A, Sievers K. Association of overweight, trauma and workload with arthrosis. A health survey of 7,217 persons. Acta Orthop Scand 1993; 513–518.

    Google Scholar 

  62. Felson D. Weight and Osteoarthritis. J Rheumatol 1995; 22:43(Suppl):7S–9S.

    Google Scholar 

  63. Felson D, Zhang Y, Anthony J, Naimark A, Anderson J. Weight loss reduces the risk for subsequent symptomatic knee osteoarthritis in women. Ann Int Med 1992; 116: 535539.

    Google Scholar 

  64. McGoey BV, Deitel M, Saplys RJF, Kliman ME. Effect of weight loss on musculoskeletal pain in the morbidly obese. Bone Joint Surg 1990; 72B: 322–323.

    CAS  Google Scholar 

  65. Garfinkle L. Overweight and cancer. Ann Int Med 1985; 103 (6 pt 2): 1034–1036.

    Google Scholar 

  66. Hulka BS, Edison TI, Lininger R. Steroid hormones and risks of breast cancer. Cancer Supp 1994; 74: 1111–1124.

    CAS  Google Scholar 

  67. Sugerman HJ, Fairman RP, Baron PL, Kwentus JA. Gastric surgery for respiratory insufficiency of obesity. Chest 1986; 90: 81–86.

    Article  CAS  Google Scholar 

  68. Findley LJ, Levinson MP, Bonnie RI. Driving performance and automobile accidents in patients with sleep apnea. Clin Chest Med 1992; 13: 427–435.

    CAS  Google Scholar 

  69. Wiegand L, Zwillich C. Obstructive sleep apnea. Disease-a-Month 1994; XL:197–252.

    Google Scholar 

  70. Shelton KE, Woodson H, Gay S, Suratt PM. Pharyngeal ft in obstructive sleep apnea. Am Rev Respir Dis 1993; 148: 462–466.

    CAS  Google Scholar 

  71. Suratt PM, McTier RF, Findley LJ, Pohl SL, Wilhoit SC. Effect of very-low calorie diets with weight loss on obstructive sleep apnea. Am J Clin Nutr 1992; 56: 182S - 184S.

    CAS  Google Scholar 

  72. Smith PL, Gold AR, Haponik EF, Bleeker ER. Weight loss in mildly to morbidly obese patients with obstructive sleep apnea. Ann Intern Med 1985; 103: 850–855.

    CAS  Google Scholar 

  73. Charuzi I, Lavie P, Peiser J, Peled R. Bariatric surgery in morbidly obese sleep apne patients: short-and long-term follow up. Am J Clin Nutr 1992; 55: 594S - 596S.

    CAS  Google Scholar 

  74. Campfield LA. Treatment options and the maintenanace of weight loss in obesity treatment. In: Allison DB and Pi-Sunyer FX, eds. Obesity Treatment: Establishing Goal, Improving Outcome, Reviewing the Research Agenda. Plenum, New York, NY, 1995, pp. 93–95.

    Google Scholar 

  75. Blackburn GL, Ishikawa M, Miller D. Biomarkers to characterize various type of obesity. Obesity Assessment. In: St. Jeor S, ed. Tools, methods, interpretations: Reno-Diet-Heart Study. Chapman & Hall Series in Clinical Nutrition, Chapman & Hall, New York, NY, pp. 101–113.

    Google Scholar 

  76. Predicting treatment outcome: why we have been so unsuccessful. In: Allison DB, Engel CN, Pi-Sunyer FX, eds. Obesity Treatment: Establishing Goals, Improving Outcomes, and Reviewing the Research Agenda. Plenum, New York, NY, 1995, pp. 191–198.

    Google Scholar 

  77. Weintraub M. Long-term weight control study: conclusions. Clin Pharmacol Ther 1992; 51: 642–646.

    Article  CAS  Google Scholar 

  78. Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997; 337(9):581–588.

    Article  CAS  Google Scholar 

  79. Cheng TO, Mitral valve disease associated with use of anorexigenic medications. Ann Thoracic Surg 1998; 65(1):298–299.

    CAS  Google Scholar 

  80. Lean ME. Sibutramine-a review of clinical efficacy. Int J Obes Relat Metab Disord. 1997; 21(1)S360–S366; discussion 37–139.

    Google Scholar 

  81. Bray GA, Ryan DH, Gordon D, Heidingsfelder S, Cerise F, Wilson K. A double-blind randomized placebo-controlled trial of sibutramine. Obes Res 1996; 4 (3): 263–270.

    Article  CAS  Google Scholar 

  82. Heal DJ, Aspley S, Prow MR, Jackson HC, Martin KF, Cheetham SC. Sibutramine: a novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from d-amphetamine and d-fenfluramine Int J Obes 1998; 22 (1): 518 - S28.

    Google Scholar 

  83. Sjostrom L. Obesity: a time bomb to be defused. Lancet 1998; 352: 167.

    Article  CAS  Google Scholar 

  84. Sjostrom L, Rissanen A, Anderson T, Boldrin M, Golay A, Koppeschaar Hans PF, et al. Randomized placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. The Lancet. 1998; 352(9123)167.

    Google Scholar 

  85. Hollander PA, Elbein SC, Hirsch IB, Kelley D, McGill J, Taylor T, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. Diabetes Care 1998; 21 (8): 1288–1294.

    Article  CAS  Google Scholar 

  86. Blackburn GL, Ishikawa M. Intensive diet and surgical management of obesity. Cuff Opin Endocrinol Diabetes 1996; 3: 66–73.

    Article  Google Scholar 

  87. Schlundt DG, Hill JO, Pope-Cordle J, Arnold D, Virts KL, Katahn M. Randomized evaluation of a low fat ad libitum carbohydrate diet for weight reduction. Int J Obes Relat Metab Disord 1993; 17: 623–629.

    CAS  Google Scholar 

  88. Katzel LI, Bleeker ER, Colman EG, Rogus EM, Sorkin JD, Goldberg AP. Effects of weight loss vs aerobic exercise training on risk factors for coronary disease in healthy, obese, middle-aged and older men. A randomized controlled trial. JAMA 1995; 274: 1915–1921.

    Article  CAS  Google Scholar 

Download references

Authors
  1. Margaret C. Flynn
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Samuel Chan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. George L. Blackburn
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Lilly Research Laboratories, Indiana University School of Medicine, Indianapolis, IN, USA

    David J. Goldstein MD, PhD

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Springer Science+Business Media New York

About this chapter

Cite this chapter

Flynn, M.C., Chan, S., Blackburn, G.L. (1999). Syndrome X and the Benefits of Weight Loss. In: Goldstein, D.J. (eds) The Management of Eating Disorders and Obesity. Nutrition ◊ and ◊ Health. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-694-2_10

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-694-2_10

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4757-6761-2

  • Online ISBN: 978-1-59259-694-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation